Annual report
7733.TEDINET S100TNZ4
Period2023-04-01 → 2024-03-31
Filed2024-06-20
StandardIFRS
ConsolidatedYes
Data checks19 of 19 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥936.2bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥881.9bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥750.1bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥730.5bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥755.2bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥43.6bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥186.6bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥35.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥182.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥141.7bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥76.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥86.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥242.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥143.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥115.7bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥12.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥51.7bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥242.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥143.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥1.53T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.51T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.36T | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥1.18T | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥1.02T | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥777.0bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥867.5bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥757.2bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥641.2bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥511.4bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥757.2bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥640.1bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥510.2bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥394.3bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥370.7bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥340.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥169.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.5bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥302.6bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥217.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥162.7bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥42.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥98.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥169.7bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥124.1bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥133.5bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | ¥360.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥58.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥71.0bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥118.9bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥62.4bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥276.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥143.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥40.7bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥40.8bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥19.5bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥199.91 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥113.22 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥90.22 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥10.05 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥39.37 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥199.44 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥113.08 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥90.17 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥10.04 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥39.36 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥649.59 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥510.62 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥400.75 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥306.72 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥288.39 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 49.4% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 42.4% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 37.6% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 33.3% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 36.5% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 34.7% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 24.9% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 25.6% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 3.4% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.7% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 28,838 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 32,805 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 31,557 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 31,653 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 35,174 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥379.4bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥380.0bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥378.6bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥344.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥375.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥41.9bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥82.0bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥135.1bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥152.3bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥57.2bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥49.0bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥13.3bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥382.1bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥165.4bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥293.6bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥130.3bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥84.8bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥8.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥9.9bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥954.9bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥973.6bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥900.9bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥826.6bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥771.0bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥442.0bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥555.3bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥512.9bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥418.3bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥357.2bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥349.8bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥376.2bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥190.1bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥4m | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥241.97 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥102.88 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.13 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥6.64 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥7.51 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥241.41 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥102.76 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥66.1 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥6.64 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥7.51 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥18 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥16 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥12 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥10 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥439.81 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥333.48 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥280.3 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥271.69 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥292.24 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 53.7% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.9% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.6% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.3% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 63.1% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 33.6% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 24.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.4% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,215,147,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,266,179,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,299,294,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,370,915,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,370,915,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 2,834 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 2,727 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 3,478 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 4,775 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 7,146 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 441 pure |
| Otherother segments | capex | 2023-04-01 → 2024-03-31 | ¥1.5bn |
| Otherother segments | segment assets | at 2024-03-31 | ¥12.7bn |
| Otherother segments | segment profit | 2023-04-01 → 2024-03-31 | −¥7.8bn |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥9.3bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥415.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥44.8bn |
| Endoscopicreportable segment | employees | at 2024-03-31 | 14948 pure |
| Endoscopic Solutionsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥50.7bn |
| Endoscopic Solutionsreportable segment | segment assets | at 2024-03-31 | ¥637.0bn |
| Endoscopic Solutionsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥104.7bn |
| Therapeuticreportable segment | employees | at 2024-03-31 | 8337 pure |
| Therapeutic Solutionsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥19.3bn |
| Therapeutic Solutionsreportable segment | segment assets | at 2024-03-31 | ¥469.2bn |
| Therapeutic Solutionsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥8.5bn |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥71.4bn |
| —segment total | segment assets | at 2024-03-31 | ¥1.12T |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥88.4bn |
| Otherother segments | capex | 2022-04-01 → 2023-03-31 | ¥1.4bn |
| Otherother segments | segment assets | at 2023-03-31 | ¥20.6bn |
| Otherother segments | segment profit | 2022-04-01 → 2023-03-31 | −¥914m |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥11.7bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥479.2bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥28.9bn |
| Endoscopic Solutionsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥43.0bn |
| Endoscopic Solutionsreportable segment | segment assets | at 2023-03-31 | ¥555.9bn |
| Endoscopic Solutionsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥152.8bn |
| Therapeutic Solutionsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥15.9bn |
| Therapeutic Solutionsreportable segment | segment assets | at 2023-03-31 | ¥453.0bn |
| Therapeutic Solutionsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥63.7bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥60.3bn |
| —segment total | segment assets | at 2023-03-31 | ¥1.03T |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥215.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 2 pure |
| Endoscopicreportable segment | employees | at 2024-03-31 | 729 pure |
| Therapeuticreportable segment | employees | at 2024-03-31 | 361 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,936
| Item | Context | Value | Unit |
|---|---|---|---|
| Transfer of collagen business and dental product sales businesses other income IFRS | CurrentYearDuration | 1127000000 | JPY |
| Business restructuring expenses IFRS | Prior1YearDuration | 2361000000 | JPY |
| Quality assurance expenses other expenses IFRS | Prior1YearDuration | 1937000000 | JPY |
| Quality assurance expenses other expenses IFRS | CurrentYearDuration | 23041000000 | JPY |
| Losses related with veran medical technologies inc other expenses IFRS | CurrentYearDuration | 51886000000 | JPY |
| Career support for external opportunity IFRS | CurrentYearDuration | 5851000000 | JPY |
| Conclusion and cancellation of share purchase agreement other expenses IFRS | CurrentYearDuration | 1966000000 | JPY |
| Loss related to the orthopedic surgery business other expenses IFRS | CurrentYearDuration | 8588000000 | JPY |
| Financial assets measured at amortized cost interest income IFRS | Prior1YearDuration | 3702000000 | JPY |
| Financial assets measured at amortized cost interest income IFRS | CurrentYearDuration | 2365000000 | JPY |
| Financial assets measured at fair value through other comprehensive income dividend income IFRS | Prior1YearDuration | 38000000 | JPY |
| Financial assets measured at fair value through other comprehensive income dividend income IFRS | CurrentYearDuration | 11000000 | JPY |
| Other finance income IFRS | Prior1YearDuration | 120000000 | JPY |
| Other finance income IFRS | CurrentYearDuration | 186000000 | JPY |
| Finance income IFRS | Prior1YearDuration | 3860000000 | JPY |
| Finance income IFRS | CurrentYearDuration | 2562000000 | JPY |
| Financial liabilities measured at amortized cost interest expenses IFRS | Prior1YearDuration | 4974000000 | JPY |
| Financial liabilities measured at amortized cost interest expenses IFRS | CurrentYearDuration | 4575000000 | JPY |
| Financial liabilities measured at amortized cost bond interest finance costs IFRS | Prior1YearDuration | 891000000 | JPY |
| Financial liabilities measured at amortized cost bond interest finance costs IFRS | CurrentYearDuration | 834000000 | JPY |
| Foreign exchange loss IFRS | Prior1YearDuration | 2141000000 | JPY |
| Foreign exchange loss IFRS | CurrentYearDuration | 4487000000 | JPY |
| Other finance costs IFRS | Prior1YearDuration | 169000000 | JPY |
| Other finance costs IFRS | CurrentYearDuration | 410000000 | JPY |
| Finance costs IFRS | Prior1YearDuration | 8175000000 | JPY |
| Finance costs IFRS | CurrentYearDuration | 10306000000 | JPY |
| Cash and deposits | Prior1YearInstant_NonConsolidatedMember | 4000000 | JPY |
| Cash and deposits | CurrentYearInstant_NonConsolidatedMember | 190105000000 | JPY |
| Notes receivable trade | Prior1YearInstant_NonConsolidatedMember | 2000000 | JPY |
| Notes receivable trade | CurrentYearInstant_NonConsolidatedMember | 3000000 | JPY |
| Accounts receivable trade | Prior1YearInstant_NonConsolidatedMember | 59690000000 | JPY |
| Accounts receivable trade | CurrentYearInstant_NonConsolidatedMember | 67070000000 | JPY |
| Finished goods | Prior1YearInstant_NonConsolidatedMember | 39527000000 | JPY |
| Finished goods | CurrentYearInstant_NonConsolidatedMember | 38795000000 | JPY |
| Work in process | Prior1YearInstant_NonConsolidatedMember | 1080000000 | JPY |
| Work in process | CurrentYearInstant_NonConsolidatedMember | 1465000000 | JPY |
| Raw materials and supplies | Prior1YearInstant_NonConsolidatedMember | 46882000000 | JPY |
| Raw materials and supplies | CurrentYearInstant_NonConsolidatedMember | 56075000000 | JPY |
| Short term loans receivable | Prior1YearInstant_NonConsolidatedMember | 72521000000 | JPY |
| Short term loans receivable | CurrentYearInstant_NonConsolidatedMember | 50056000000 | JPY |
| Accounts receivable other | Prior1YearInstant_NonConsolidatedMember | 56143000000 | JPY |
| Accounts receivable other | CurrentYearInstant_NonConsolidatedMember | 36357000000 | JPY |
| Income taxes receivable | Prior1YearInstant_NonConsolidatedMember | － | JPY |
| Income taxes receivable | CurrentYearInstant_NonConsolidatedMember | 23344000000 | JPY |
| Other ca | Prior1YearInstant_NonConsolidatedMember | 10805000000 | JPY |
| Other ca | CurrentYearInstant_NonConsolidatedMember | 6698000000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant_NonConsolidatedMember | -1923000000 | JPY |
| Allowance for doubtful accounts ca | CurrentYearInstant_NonConsolidatedMember | -897000000 | JPY |
| Current assets | Prior1YearInstant_NonConsolidatedMember | 284731000000 | JPY |
| Current assets | CurrentYearInstant_NonConsolidatedMember | 469071000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 19 of 19 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |